Hyman Charles D Has $623,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Hyman Charles D lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,554 shares of the medical instruments supplier’s stock after buying an additional 134 shares during the quarter. Hyman Charles D’s holdings in Becton, Dickinson and Company were worth $623,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Ontario Teachers Pension Plan Board raised its stake in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock worth $461,158,000 after purchasing an additional 1,263,391 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after purchasing an additional 516,427 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 11.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after purchasing an additional 512,566 shares in the last quarter. Royal Bank of Canada raised its stake in Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after purchasing an additional 473,914 shares in the last quarter. Finally, Morgan Stanley raised its stake in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $281.40.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $0.56 during midday trading on Tuesday, hitting $237.14. The stock had a trading volume of 1,120,070 shares, compared to its average volume of 1,408,706. The company’s 50-day moving average price is $238.27 and its 200-day moving average price is $239.97. The company has a market capitalization of $68.54 billion, a P/E ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.86 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.